#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4622	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1960	427.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1401	1401	C	603	C	364	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8322	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3809	396.7	0	.	n	.	0	T695C	SNP	695	695	T	1215	1215	C	607	C	374	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8322	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3809	396.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1857	1857	A	408	A	264	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8322	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3809	396.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2491	2491	C	443	C	270	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8322	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3809	396.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3117	3117	T	407	T	257	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8322	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3809	396.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2565	2565	A	462	A	283	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	274	folP	852	852	100.0	folP.l15.c4.ctg.1	1706	30.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1140	1142	AGC	40;40;40	A;G;C	25;24;24	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	820	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3358	45.0	1	SNP	p	S91F	0	.	.	271	273	TCC	649	651	TCC	54;54;54	T;C;C	35;35;37	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	820	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3358	45.0	1	SNP	p	D95N	0	.	.	283	285	GAC	661	663	GAC	66;66;66	G;A;C	44;44;43	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	820	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3358	45.0	1	SNP	p	D95G	0	.	.	283	285	GAC	661	663	GAC	66;66;66	G;A;C	44;44;43	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	210	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1301	31.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	431	433	ACC	50;51;48	A;C;C	30;32;31	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	210	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1301	31.2	0	.	p	.	0	R44H	NONSYN	130	132	CGC	446	448	CAC	49;49;49	C;A;C	29;29;30	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	210	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1301	31.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	629	631	CAC	42;41;41	C;A;C	28;25;26	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	210	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1301	31.2	1	SNP	p	G45D	0	.	.	133	135	GGC	449	451	GGC	49;49;49	G;G;C	31;29;30	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	232	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	653	62.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	734	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2810	47.4	1	SNP	p	D86N	0	.	.	256	258	GAC	573	575	GAC	56;56;56	G;A,C;C	34;31,1;34	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	734	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2810	47.4	1	SNP	p	S87I	0	.	.	259	261	AGT	576	578	AGT	56;56;56	A;G;T	32;33;33	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	734	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2810	47.4	1	SNP	p	S87R	0	.	.	259	261	AGT	576	578	AGT	56;56;56	A;G;T	32;33;33	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	734	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2810	47.4	1	SNP	p	S87W	0	.	.	259	261	AGT	576	578	AGT	56;56;56	A;G;T	32;33;33	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	734	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2810	47.4	1	SNP	p	S88P	0	.	.	262	264	TCC	579	581	TCC	56;56;56	T;C;C	33;32;35	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	664	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2755	44.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1595	1597	GGC	37;37;37	G;G;C	23;21;25	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1298	1300	GCA	97;97;97	G;C;A	64;63;66	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1301	1303	ATC	97;97;97	A;T;C	65;64;64	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1313	1315	GTG	96;96;96	G;T;G	63;60;63	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1313	1315	GTG	96;96;96	G;T;G	63;60;63	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1817	1819	ACC	47;47;45	A;C;C	29;35;30	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1871	1873	GCG	34;32;31	G;C;G	28;23;22	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1871	1873	GCG	34;32;31	G;C;G	28;23;22	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1994	1996	GGC	41;41;41	G;G;C	29;28;24	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2003	2005	GGC	30;30;30	G;G;C	21;21;20	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	716	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2265	58.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2021	2023	CCG	31;30;30	C;C;G	20;19;18	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	1354	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	2891	79.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1427	1429	CTG	53;53;54	C;T;G	30;31;32	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	1354	ponA	2397	152	96.71	ponA.l6.c4.ctg.3	495	0.3	0	.	p	.	0	Y574trunc	TRUNC	1720	1720	T	130	130	T	ND	ND	ND	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	1354	ponA	2397	152	96.71	ponA.l6.c4.ctg.3	495	0.3	0	.	p	.	0	V576G	NONSYN	1726	1728	GTA	136	138	GGA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	1354	ponA	2397	152	96.71	ponA.l6.c4.ctg.3	495	0.3	0	.	p	.	0	A578S	NONSYN	1732	1734	GCG	142	144	TCG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	1354	ponA	2397	152	96.71	ponA.l6.c4.ctg.3	495	0.3	0	.	p	.	0	N579D	NONSYN	1735	1737	AAC	145	147	GAC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	422	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1845	40.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	596	596	C	27	C	14	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	419	421	GGA	56;56;56	G;G;A	37;37;37	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	G50N	NONSYN	148	150	GGC	425	427	AAC	56;56;55	A;A;C	37;37;37	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	680	682	CTT	50;50;50	C;T;T	34;33;35	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	704	706	GGA	56;59;59	G;G;A	36;37;36	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	788	790	GGT	81;81;78	G;G;T,A	50;50;47,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	842	844	AGC	81;80;77	A;G;C	49;49;48	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	908	908	T	66	T	44	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	1	SNP	p	G120K	0	.	.	358	360	GGT	635	637	GGT	40;44;45	G;G;T	28;32;30	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	1	SNP	p	A121N	0	.	.	361	363	GCC	638	640	GCC	45;45;45	G;C;C	30;31;30	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	406	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1530	50.1	1	SNP	p	A121D	0	.	.	361	363	GCC	638	640	GCC	45;45;45	G;C;C	30;31;30	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2156	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4710	84.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1840	1842	AAT	98;99;98	A;A;T	63;63;63	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	192	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1027	34.9	1	SNP	p	V57M	1	.	.	169	171	ATG	429	431	ATG	84;78;81	A;T;G	52;50;52	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
